Predictive biomarkers for the responsiveness of recurrent glioblastomas to activated killer cell immunotherapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-3701
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Predictive biomarkers for the responsiveness of recurrent glioblastomas to activated killer cell immunotherapy ; volume:13 ; number:1 ; day:24 ; month:1 ; year:2023 ; pages:1-16 ; date:12.2023
Cell & bioscience ; 13, Heft 1 (24.1.2023), 1-16, 12.2023
- Creator
-
Hwang, Sohyun
Lim, Jaejoon
Kang, Haeyoun
Jeong, Ju-Yeon
Joung, Je-Gun
Heo, Jinhyung
Jung, Daun
Cho, Kyunggi
An, Hee Jung
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13578-023-00961-4
- URN
-
urn:nbn:de:101:1-2023033121194325238161
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hwang, Sohyun
- Lim, Jaejoon
- Kang, Haeyoun
- Jeong, Ju-Yeon
- Joung, Je-Gun
- Heo, Jinhyung
- Jung, Daun
- Cho, Kyunggi
- An, Hee Jung
- SpringerLink (Online service)
Other Objects (12)
Natural killer cell immunotherapy in glioblastoma
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy
Nanomaterial‐Boosted Tumor Immunotherapy Through Natural Killer Cells
Natural killer cells: a promising immunotherapy for cancer
Natural killer cell-based immunotherapy for acute myeloid leukemia
Bioinspired Preservation of Natural Killer Cells for Cancer Immunotherapy
Somatic retrotransposition is infrequent in glioblastomas
Immunotherapy responsiveness and risk of relapse in Down syndrome regression disorder
Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain
Cytokine-induced memory-like natural killer cells for cancer immunotherapy
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Activated Natural Killer Cells Hit Neurogenesis in the Aging Brain
Natural killer cell immunotherapy in glioblastoma
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy
Nanomaterial‐Boosted Tumor Immunotherapy Through Natural Killer Cells
Natural killer cells: a promising immunotherapy for cancer
Natural killer cell-based immunotherapy for acute myeloid leukemia
Bioinspired Preservation of Natural Killer Cells for Cancer Immunotherapy
Somatic retrotransposition is infrequent in glioblastomas
Immunotherapy responsiveness and risk of relapse in Down syndrome regression disorder
Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain
Cytokine-induced memory-like natural killer cells for cancer immunotherapy
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Activated Natural Killer Cells Hit Neurogenesis in the Aging Brain
Natural killer cell immunotherapy in glioblastoma
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy
Nanomaterial‐Boosted Tumor Immunotherapy Through Natural Killer Cells
Natural killer cells: a promising immunotherapy for cancer
Natural killer cell-based immunotherapy for acute myeloid leukemia
Bioinspired Preservation of Natural Killer Cells for Cancer Immunotherapy
Somatic retrotransposition is infrequent in glioblastomas
Immunotherapy responsiveness and risk of relapse in Down syndrome regression disorder
Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain
Cytokine-induced memory-like natural killer cells for cancer immunotherapy
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy